Marshall Wace LLP purchased a new position in shares of Oxford Immunotec Global PLC (NASDAQ:OXFD) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 68,779 shares of the company’s stock, valued at approximately $1,185,000. Marshall Wace LLP owned about 0.26% of Oxford Immunotec Global as of its most recent SEC filing.
Several other hedge funds also recently made changes to their positions in the business. BNP Paribas Arbitrage SA raised its holdings in shares of Oxford Immunotec Global by 59,988.9% in the first quarter. BNP Paribas Arbitrage SA now owns 5,408 shares of the company’s stock worth $93,000 after acquiring an additional 5,399 shares during the last quarter. Squarepoint Ops LLC raised its holdings in shares of Oxford Immunotec Global by 36.1% in the fourth quarter. Squarepoint Ops LLC now owns 19,303 shares of the company’s stock worth $247,000 after acquiring an additional 5,120 shares during the last quarter. Rhumbline Advisers raised its holdings in shares of Oxford Immunotec Global by 50.7% in the fourth quarter. Rhumbline Advisers now owns 32,758 shares of the company’s stock worth $419,000 after acquiring an additional 11,022 shares during the last quarter. Acadian Asset Management LLC raised its holdings in shares of Oxford Immunotec Global by 972.3% in the first quarter. Acadian Asset Management LLC now owns 33,969 shares of the company’s stock worth $586,000 after acquiring an additional 30,801 shares during the last quarter. Finally, Bessemer Group Inc. acquired a new position in shares of Oxford Immunotec Global in the fourth quarter worth $778,000. Institutional investors own 91.18% of the company’s stock.
OXFD has been the subject of a number of recent analyst reports. Zacks Investment Research downgraded HEXO from a “hold” rating to a “sell” rating in a research report on Wednesday, May 15th. BidaskClub downgraded Zynerba Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, June 26th. TheStreet downgraded TRI Pointe Group from a “b-” rating to a “c+” rating in a research report on Monday. Finally, ValuEngine raised Zynerba Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, April 1st. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $18.00.
Shares of NASDAQ:OXFD traded up $0.19 during trading on Thursday, hitting $13.10. The company’s stock had a trading volume of 201,827 shares, compared to its average volume of 173,810. The company has a quick ratio of 12.03, a current ratio of 12.60 and a debt-to-equity ratio of 0.04. Oxford Immunotec Global PLC has a fifty-two week low of $11.66 and a fifty-two week high of $19.19. The firm’s 50-day simple moving average is $14.07. The stock has a market capitalization of $350.63 million, a P/E ratio of 25.69 and a beta of 0.35.
Oxford Immunotec Global (NASDAQ:OXFD) last released its quarterly earnings results on Thursday, May 9th. The company reported ($0.06) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.20) by $0.14. Oxford Immunotec Global had a return on equity of 13.56% and a net margin of 172.27%. The business had revenue of $14.79 million for the quarter, compared to analysts’ expectations of $13.74 million. During the same quarter in the previous year, the firm posted ($0.40) earnings per share. The company’s revenue was up 26.6% compared to the same quarter last year. Equities research analysts forecast that Oxford Immunotec Global PLC will post -0.24 EPS for the current year.
Oxford Immunotec Global Profile
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States. It develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions.
Featured Article: How to calculate the annual rate of depreciation
Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.